Daiichi Sankyo takes over U3 Pharma
Japanese drugmaker Daiichi Sankyo has negotiated a deal to acquire all shares of the German biotechnology company U3 Pharma.
Daiichi Sankyo will purchase 100% of U3 stock and make a one-off payment of 150.0 million euros ($232.7 million). The deal is subject to the standard clearances, after which Daiichi Sankyo will have full control of the company.
U3 was founded in 2001 by Axel Ulrich of the Max Planck Institute of Biochemistry and is based in Martinsried, Germany, where it employs 27 people. Investors include Alta, Atlas Venture, E de Rothschild Investment, Life Science and Kartsen Henco. The company's focus is on programs for fully-human antibody therapies for breast, lung and colorectal cancers, and has already helped in the development of blockbusters such as Genentech's Herceptin (trastuzumab) and Pfizer's Sutent (sunitinib malate).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze